The global scientific publications on gut microbiota in type 2 diabetes; a bibliometric, Scientometric, and descriptive analysis.
Bibliometrics
Gut microbiota
Microbiome
Probiotic
Scientometrics
Type 2 diabetes
Journal
Journal of diabetes and metabolic disorders
ISSN: 2251-6581
Titre abrégé: J Diabetes Metab Disord
Pays: Switzerland
ID NLM: 101590741
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
27
04
2021
accepted:
17
10
2021
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Modifying gut dysbiosis has achieved great success in managing type 2 diabetes mellitus (T2DM) and also T2DM affected the gut microbial composition. To determine the research trend of scientific publications on the relationship between gut microbiota and T2DM through a bibliometric and descriptive approach. We included originals and reviews related to both topics of gut microbiota and T2DM through searching in Scopus up to 31 December 2019 and then characterized their bibliometric profiles including the number of publications, citations, institutions, journals, countries, and the collaboration network of authors, countries, terms and keywords. Moreover, we performed a descriptive evaluation of the clinical trials based on their intervention type and its influence on gut dysbiosis. We achieved 877 articles (436 originals and 441 reviews) according to our inclusion criteria. The annual publications were constantly increased over time and reached 220 publications in 2019. Out of 436 original articles, 231 animal studies and 174 human studies were found. The majority of human studies were clinical trials ( The exponentially growing documents on gut microbiota and T2DM had been published during the last decade and revealed gut microbiota alteration mediated antidiabetic effect of many interventions. Thus, we suggest other researchers to consider this pathway in efficacy assessment of therapeutic modalities and to find the optimal composition of gut microbiota that guarantees healthy insulin sensitivity. The online version contains supplementary material available at 10.1007/s40200-021-00920-1.
Sections du résumé
Background
UNASSIGNED
Modifying gut dysbiosis has achieved great success in managing type 2 diabetes mellitus (T2DM) and also T2DM affected the gut microbial composition.
Objectives
UNASSIGNED
To determine the research trend of scientific publications on the relationship between gut microbiota and T2DM through a bibliometric and descriptive approach.
Method
UNASSIGNED
We included originals and reviews related to both topics of gut microbiota and T2DM through searching in Scopus up to 31 December 2019 and then characterized their bibliometric profiles including the number of publications, citations, institutions, journals, countries, and the collaboration network of authors, countries, terms and keywords. Moreover, we performed a descriptive evaluation of the clinical trials based on their intervention type and its influence on gut dysbiosis.
Results
UNASSIGNED
We achieved 877 articles (436 originals and 441 reviews) according to our inclusion criteria. The annual publications were constantly increased over time and reached 220 publications in 2019. Out of 436 original articles, 231 animal studies and 174 human studies were found. The majority of human studies were clinical trials (
Conclusion
UNASSIGNED
The exponentially growing documents on gut microbiota and T2DM had been published during the last decade and revealed gut microbiota alteration mediated antidiabetic effect of many interventions. Thus, we suggest other researchers to consider this pathway in efficacy assessment of therapeutic modalities and to find the optimal composition of gut microbiota that guarantees healthy insulin sensitivity.
Supplementary Information
UNASSIGNED
The online version contains supplementary material available at 10.1007/s40200-021-00920-1.
Identifiants
pubmed: 35673416
doi: 10.1007/s40200-021-00920-1
pii: 920
pmc: PMC9167415
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13-32Informations de copyright
© Springer Nature Switzerland AG 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
Obes Surg. 2017 Apr;27(4):917-925
pubmed: 27738970
FASEB J. 2008 Feb;22(2):338-42
pubmed: 17884971
Annu Rev Med. 2011;62:361-80
pubmed: 21226616
EBioMedicine. 2020 Jan;51:102590
pubmed: 31901868
Medicine (Baltimore). 2017 Sep;96(37):e7338
pubmed: 28906350
J Cancer. 2020 Jun 7;11(16):4823-4831
pubmed: 32626529
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5
pubmed: 16033867
mSystems. 2017 Mar 21;2(2):
pubmed: 28345059
Genome Res. 2009 Dec;19(12):2317-23
pubmed: 19819907
ISME J. 2017 Sep;11(9):2035-2046
pubmed: 28524868
PeerJ. 2018 Jun 29;6:e5091
pubmed: 29967745
Digestion. 2014;89(1):31-6
pubmed: 24458110
Obes Surg. 2012 May;22(5):740-8
pubmed: 22354457
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Diabetologia. 2009 Jan;52(1):17-30
pubmed: 18941734
Diabetes. 2008 Jun;57(6):1470-81
pubmed: 18305141
Cochrane Database Syst Rev. 2014 Aug 08;(8):CD003641
pubmed: 25105982
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
PLoS One. 2014 Jul 02;9(7):e100778
pubmed: 24988476
J Diabetes Metab Disord. 2020 Jan 15;19(1):163-177
pubmed: 32550166
Nat Rev Endocrinol. 2014 Mar;10(3):143-56
pubmed: 24393785
Proc Nutr Soc. 2015 Aug;74(3):328-36
pubmed: 25497601
Lipids Health Dis. 2016 Jun 18;15:108
pubmed: 27317359
Gene. 2014 Mar 1;537(1):85-92
pubmed: 24325907
Biosci Biotechnol Biochem. 2007 May;71(5):1236-43
pubmed: 17485860
Obes Surg. 2016 Feb;26(2):410-21
pubmed: 26530712
Diabetes. 2012 Feb;61(2):364-71
pubmed: 22190648
JAMA. 2009 Sep 9;302(10):1092-6
pubmed: 19738094
Gut. 2011 Sep;60(9):1214-23
pubmed: 21572120
World J Gastroenterol. 2014 Dec 21;20(47):17737-45
pubmed: 25548472
J Diabetes Res. 2020 Sep 28;2020:7253978
pubmed: 33062716
Nat Med. 2018 Dec;24(12):1919-1929
pubmed: 30397356
Nature. 2006 Dec 21;444(7122):1022-3
pubmed: 17183309
Nutr Rev. 2016 Dec;74(12):774-784
pubmed: 27864537
Diabetes. 2009 Jul;58(7):1509-17
pubmed: 19366864
Best Pract Res Clin Gastroenterol. 2013 Feb;27(1):73-83
pubmed: 23768554
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
Dermatol Ther. 2020 Jul;33(4):e13434
pubmed: 32314483
Genome Biol. 2011;12(5):R50
pubmed: 21624126
PeerJ. 2017 Jun 20;5:e3443
pubmed: 28649469
PLoS One. 2012;7(4):e35240
pubmed: 22506074
Appl Environ Microbiol. 2014 Oct;80(19):5935-43
pubmed: 25038099
mBio. 2018 May 22;9(3):
pubmed: 29789365
Cell Metab. 2015 Aug 4;22(2):228-38
pubmed: 26244932
Dermatol Ther. 2020 Jul;33(4):e13395
pubmed: 32277530
Mol Syst Biol. 2013;9:640
pubmed: 23340846
World J Gastroenterol. 2015 Jan 21;21(3):803-14
pubmed: 25624713
Nat Med. 2017 Jul;23(7):850-858
pubmed: 28530702
Endocrinology. 2013 Oct;154(10):3552-64
pubmed: 23885020
Int J Food Sci Nutr. 2018 Sep;69(6):729-740
pubmed: 29199483
Curr Diab Rep. 2018 Jun 21;18(8):55
pubmed: 29931613
Iran J Basic Med Sci. 2019 Jan;22(1):65-71
pubmed: 30944710
Front Psychiatry. 2021 Jan 08;11:587670
pubmed: 33488420
Nat Biotechnol. 2019 Feb;37(2):186-192
pubmed: 30718869
Int J Impot Res. 2020 Jul;32(4):409-419
pubmed: 31235897
J Clin Invest. 2015 Mar 2;125(3):939-48
pubmed: 25729850